This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Citi Sticks to Its Sell Rating for Baxter International (BAX)

Tipranks - Tipranks - Thu Jul 9, 4:54AM CDT

Citi analyst Joanne Wuensch maintained a Sell rating on Baxter International on July 6 and set a price target of $17.00. The company’s shares closed yesterday at $22.58.

55% Off TipRanks

According to TipRanks, Wuensch is a 3-star analyst with an average return of 1.3% and a 52.74% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Integra Lifesciences, Abbott Laboratories, and Edwards Lifesciences.

Currently, the analyst consensus on Baxter International is a Hold with an average price target of $21.14.

See Insiders’ Hot Stocks on TipRanks >>

Based on Baxter International’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2.7 billion and a GAAP net loss of $15 million. In comparison, last year the company earned a revenue of $2.63 billion and had a net profit of $126 million

Read More on BAX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).